TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02043067

Intervention type: OTHER
Intervention: Comprehensive TB screening
Description: All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
Study: NCT00442156

Intervention type: PROCEDURE
Intervention: Laser photocoagulation
Description: modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
Study: NCT03578913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK crown
Description: The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEK crown
Description: The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM Crown
Description: Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM Crown
Description: Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
Study: NCT04400747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
Study: NCT01830686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugarcane bagasse
Description: One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-caloric, non-fermentable fiber
Description: One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Minimal fiber
Description: One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
Study: NCT02456389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative risk stratification
Description: Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative risk stratification
Description: Postoperative risk-prediction tool based on intraoperative variables
Study: NCT04484168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Terminal Interruption of the Reflux Source
Description: Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axial Ablation
Description: Endovenous ablation of venous reflux in the main superficial veins of the leg
Study: NCT00260611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study: NCT02456389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of care
Description: Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
Study: NCT02456480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001
Description: topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001
Description: topical gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel
Study: NCT00204243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: surgically implanted naltrexone releasing during 5 to 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
Study: NCT06208930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
Study: NCT01007253

Intervention type: DRUG
Group type: OTHER
Intervention: PL nasal spray
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL nasal spray
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL nasal spray
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL nasal spray
Description: 2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate (FF)
Description: 2 puffs of FF nasal spray in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate (FF)
Description: 2 puffs of FF nasal spray in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate (FF)
Description: 2 puffs of FF nasal spray in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone furoate (FF)
Description: 2 puffs of FF nasal spray in each nostril once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL eye drops
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL eye drops
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL eye drops
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: PL eye drops
Description: 1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: olopatadine (OLO)
Description: 1 drop of OLO eye drops in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: olopatadine (OLO)
Description: 1 drop of OLO eye drops in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: olopatadine (OLO)
Description: 1 drop of OLO eye drops in each eye once a day for 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: olopatadine (OLO)
Description: 1 drop of OLO eye drops in each eye once a day for 1 week
Study: NCT03473938

Intervention type: DEVICE
Intervention: Spatz3 AIGB
Description: Implantation of Spatz3 AIGB balloon.
Study: NCT02012673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic lung volume reduction
Description: Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
Study: NCT02551575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX and HCQ
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TCM
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrative Medicine
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks.
Study: NCT03848078

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not.
Study: NCT01118923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium supplement (magnesium hydroxide/ -oxide)
Description: 3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo-tablets daily for 12 weeks
Study: NCT02299167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dixon's up-and-down method
Description: using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
Study: NCT00767871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: 12 week treatment with lexapro
Study: NCT04332120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal sterilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal sterilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tubal sterilization
Study: NCT00081458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injectable subcutaneously daily into thigh or abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Description: Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg/d
Description: Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
Study: NCT03419650

Intervention type: DRUG
Group type: OTHER
Intervention: ACTHar
Description: Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
Study: NCT04167800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Orthosis, mobilization, strengthening, posture and segmental breathing exercises
Study: NCT03927391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: enzalutamide treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: enzalutamide treatment
Study: NCT03823131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImmunoPulse
Description: Intratumoral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImmunoPulse
Description: Intratumoral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImmunoPulse
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CORVax
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavokinogene telseplasmid
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavokinogene telseplasmid
Description: Intratumoral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavokinogene telseplasmid
Description: Intratumoral
Study: NCT02846402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Testing
Description: The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
Study: NCT03174522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REX-001
Description: REX-001 is administered through an intra-arterial catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered through an intra-arterial catheter.
Study: NCT02941003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microscope
Description: Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microscope
Description: Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunostaining
Description: Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunostaining
Description: Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGS
Description: The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGS
Description: The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
Study: NCT00368550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline (to a maximum of 200 mg/day) for 14-week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14-week treatment period
Study: NCT03489564

Intervention type: BEHAVIORAL
Intervention: Active
Description: No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.

Intervention type: BEHAVIORAL
Intervention: Sedentary
Description: No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
Study: NCT04803500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: single injection of simvastatin gel in the gap around immediately placed implant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
Study: NCT00991432

Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study: NCT00852878

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Biofeedback will teach resonant frequency breathing for 6-8 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Protocol
Description: Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
Study: NCT03602001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentive eating smartphone application.
Description: A smartphone application that encourages a more attentive eating style.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard dietary advice and text tips.
Description: Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary advice and text tips.
Description: Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
Study: NCT01692756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog then Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenalog

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02292251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Device-assisted therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy-based occupational therapy
Study: NCT04229901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: HepaStem will be administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as an intravenous (IV) infusion
Study: NCT01706627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Melatonin
Description: Active Comparator: Drug: Melatonin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg Melatonin
Description: Active Comparator: Drug: Melatonin 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo (identical formulation and delivery, without active ingredient)
Study: NCT01257438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluency Plus Endovascular Stent Graft
Description: Treatment of in-stent restenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty only
Description: Treatment of in-stent restenosis
Study: NCT02456389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of monitoring
Description: Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-based, escalating levels of co-management
Description: Varying use of Hospitalist co-management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative care
Description: Routine postoperative care, as medically indicated
Study: NCT03943082

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Educational Materials
Description: Receive FRP brochure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Educational Materials
Description: Receive FRP brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up Care
Description: Receive follow-up phone call

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies